Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
The Prognostic Significance and Relationship with Body Composition of CCR7Positive Cells in Colorectal Cancer George Malietzis MBBS MSc MRCS 1,2,, Gui Han Lee MBBS MRCS 1,2,3, David Bernardo PhD 1, Alexandra I F Blakemore PhD 4, Stella C Knight PhD 1, Morgan Moorghen MD FRCPath3, Hafid O Al-Hassi PhD 1, John T Jenkins MD FRCS 2 1. Antigen Presentation Research Group, Imperial College London, North West London Hospitals Campus, Watford Road, Harrow HA1 3UJ, UK 2. Department of Surgery St Marks Hospital, Watford Road, Harrow, Middlesex, HA1 3UJ, UK 3. Department of Histopathology St Marks Hospital, Watford Road, Harrow, Middlesex, HA1 3UJ, UK 4. Section of Investigative Medicine, Division of Diabetes, Endocrinology, and Metabolism, Faculty of Medicine, Imperial College, London W12 0NN, UK Corresponding Author: Professor Stella C Knight Antigen Presentation Research Group, Imperial College London, North West London Hospitals Campus, Watford Road, Harrow, HA1 3UJ, United Kingdom Email: [email protected] Telephone: +44 20 8869 3494 Fax: +44 20 8869 3532 Short Title: CCR7 and Colorectal Cancer Funding sources: none Disclosures: none Synopsis: High CCR7+ cell density in colorectal cancer was associated with higher stage of disease, myosteatosis and overall worse survival. Our results suggest that a specific immune microenvironment may be associated with altered host’s body composition and disease outcomes. Abstract Background and Objectives: The host local immune response (LIR) to cancer is a determinant of cancer outcome. Regulation of this local response is largely achieved through chemokine synthesis from the tumor microenvironment such as C-Chemokine-Receptor-7 (CCR7). We examined the LIR measured as CCR7 expression, in colorectal cancers (CRC) and explored relationships with body composition (BC) and survival. Methods: A study of paraffin-embedded tissue specimens was carried out in 116 patients with non-metastatic CRC. CCR7 expression was determined by immunohistochemistry. Analysis of computer tomography scans was used to calculate BC parameters. Survival analyses and multivariate regression models were used. Results: High CCR7+ cell density within the tumor stroma and at the margin was significantly associated with increased age, the presence of lymphovascular invasion, higher tumor stage, lymph node metastasis, high Klintrup-Makinen immune score and myosteatosis. High CCR7+ cell density in the tumor margin was significantly associated with shorter disease-free (DFS) and overall survival (OS)(p<0.001). This was also significantly associated with shorter survival in multivariate analysis (HR=8.87; 95%CI(2.51-31.3); p<0.01 for OS and HR=4.72; 95%CI(1.24-12.9); p=0.02 for DFS). Conclusions: Our results suggest that a specific immune microenvironment may be associated with altered host’s BC and tumor behavior, and that CCR7 may serve as a novel prognostic biomarker. Keywords: colorectal cancer, immunology, body composition, CCR7, chemokines, outcomes Introduction Colorectal cancer (CRC) is the fourth most common cause of cancer death and the third most common cancer worldwide. Colorectal cancers are classified according to the TNM classification system. Treatment planning is based on combinations of the tumor local invasion depth (T-stage), the presence of positive lymph node (N-stage) and distant metastasis (M-stage).[1] Although the TNM staging system provides useful prognostic information, an individual patient outcome from therapy cannot be accurately predicted. Therefore, there is a need for additional prognostic markers to complement the TNM system. Virchow first described the link between cancer and inflammation, suggesting that the “lymphoreticular infiltrate” at sites of chronic inflammation reflected the origin of cancer.[2] The local tumor microenvironment plays an important role in carcinogenesis including, cell growth, invasion and metastasis and these effects are mediated via host-derived stromal cells and cytokines. Jass first, in 1986 proposed that infiltration of immune cells can act as an independent prognostic factor in CRC, and since then the local inflammatory response (LIR) has been accepted as a major factor in the pathogenesis of cancer. [3] The LIR is associated with changes in the type, density, and location of immune cells in cancer tumors and also has been linked with weight and lean muscle loss. [4],[5] Emerging data support the link between systemic inflammatory response and body composition alterations but limited information exists on how the LIR to the tumor is associated to these changes. [6] Body composition defined the proportions of fat, muscle and bone of an individual. [7] Muscle depletion is characterized by reduction in muscle size (myopenia) and an increased infiltration by inter- and intramuscular fat, described as myosteatosis.[8] Visceral obesity is defined as the excess of intra-abdominal adipose tissue accumulation.[9] These conditions are recognized as poor prognostic indicators in patients with cancer. [10] Originally, chemokines and their receptors were reported to mediate different pro- and anti-inflammatory responses.[11] LIR depends on the ability of immune cells to actively migrate in and out of tissue, and chemokines are established regulators of immune cell migration and survival. Two essential chemokines involved in cell movement during homeostasis are CC-chemokine ligand 19 (CCL-19) and 21 (CCL-21), that are ligands for the CC-chemokine receptor 7 (CCR-7). CCR7 is expressed on naıve T cells, memory T cells, B cells, and mature dendritic cells, and is considered to play an important role in lymphocyte cell trafficking and homing to lymph nodes. [12] In cancer, CCR7 expression on immune cells regulates homing of lymphocytes into secondary lymphoid organs and may also be involved in the lymphatic spread of solid tumors. [13] Evidence suggests that assessment of the CCR7 expression on CRCs specimens might improve prediction not only of the survival outcome but also of lymph node spread. [14] In the present study, we aimed to determine the expression of CCR7 on tumour infiltrating cells in primary CRC and investigate its impact on disease progression and survival. We also aimed to correlate the expression of CCR7 with the patients’ clinical and pathological parameters (including their body composition) derived from computerised tomography (CT) analysis, [15] and to explore the relationship between body composition and tumor immunology in CRC. Materials and Methods Study population A total of 242 consecutive patients with primary CRC who underwent elective resection at St Mark’s Hospital between January 2009 and December 2011 were identified from a prospective database. Patients with recurrent or metastatic disease confirmed preoperatively or at surgery, emergency cases, those receiving neoadjuvant chemotherapy and/or radiotherapy, and those with a non-available pre-operative CT were excluded. All recorded clinical and pathological data were revalidated from medical and pathology records. Data collected prospectively during the perioperative period included age, sex, Body Mass Index (BMI), histological grading, TNM stage (UICC 5 version), the presence of vascular invasion and histopathological grade of differentiation. Tissue Samples Colorectal cancer paraffin embedded tissue blocks were obtained from all the patients meeting the selection criteria. Immunohistochemical Analysis Preparation of sections from paraffin blocks was performed by standard methods. Immunohistochemical analysis of CCR7 was performed using a mouse monoclonal antibody against human CCR7 (CCR7 MAb (Clone 150503) Cat# MAB197) according to standard techniques for a Ventana Benchmark XT Autostainer (Ventana Medical Systems). Antigen retrieval was carried out using Cell Conditioning Solution (CC1-Tris-based EDTA buffer, pH 8.0; Ventana Medical Systems). Image Analysis Images of immunostained slides were digitized at 40X magnification using the Leica SCN400F. For digital quantification, image analysis software (Tissue Studio v.3.5; Definiens AG, Munich, Germany) was used to distinguish the CCR7+ cells. We focused on three main regions of interest (tumor margin, tumor stroma and tumour). Two independent assessors (GM and GHL) graphically mapped these regions using the image software. Cells were considered to either positive (+) or negative (-) according to presence of clearly defined positively stained cytoplasm in a granular distribution. Faint ill-defined staining was considered to represent an artifact and considered negative. The image analysis software was calibrated accordingly. The cell density defined as the percentage of the area containing CCR7+ cells (summed area with CCR7+ cells / total measured area x 100) was calculated for each slide. Immune score In an attempt to directly relate CCR7 expression with LIR, a previously proposed method for assessing the LIR in CRC, the Klitrup-Makinen (KM) grade was applied.[16] Briefly, using the corresponding H&E-stained sections of the study population, inflammatory cell infiltration at the invasive margin was graded using a four-point scale and subsequently classified as low grade (no increase or mild/patchy increase in inflammatory cells) or high grade (prominent inflammatory reaction forming a band at the invasive margin, or florid cup-like infiltrate at the invasive edge with destruction of cancer cell islands), by two independent assessors (GM and GHL). Discrepancies were resolved by an independent third reviewer (MM). Body Composition Analysis Images were retrieved from digital storage in the Picture Archiving and Communication System [PACS]. CT image analysis Slice-O-Matic V4.3 software (Tomovision, Montreal, Canada) was performed as described previously. [17] Briefly, total skeletal muscle and visceral adipose tissue (VAT) surface area (cm2) were evaluated on a single image at the third lumbar vertebrae (L3) using Hounsfield unit (HU) thresholds of -29 to 150 for skeletal muscle, -50 to 150 for visceral adipose tissue and -190 to -30 for subcutaneous adipose tissues. The sum of skeletal cross-sectional muscle areas was normalised for stature (m2) and reported as LSMI (cm2m-2). Mean Muscle Attenuation [MA] (HU) was reported for the whole muscle area at the third lumbar vertebra level. Reduced L3 skeletal muscle index (myopenia) and low MA (myosteatosis) were defined using predefined sex-specific skeletal muscle index cut-points. [18] Increased visceral adipose tissue area (visceral obesity) was also described by using genderspecific and pathologically relevant cut-off values. [9] Statistical Analysis The relationship between CCR7 expression and other clinicopathological parameters was assessed using nonparametric statistics. Clinical outcomes were assessed using the Kaplan-Meier survival curves, and the groups were compared using the log-rank test. Stepwise multivariate Cox proportion analysis was performed. The level of significance permitting multivariate analysis inclusion and the statistical significance for all other tests used was set at P < 0.05. All analyses were performed using the statistical software, Statistical Package for the Social Sciences, version 20.0 (SPSS, Inc, Chicago, IL). Results Patient Selection Of 242 consecutive patients undergoing surgical resection, 42 cases had a preoperative CT scan stored in a paper film form and, therefore, unsuitable for analysis, 27 had had emergency surgery, 26 had recurrent or metastatic disease at the time of surgery, 8 received neo-adjuvant treatment, and for 17 the CT analysis was not possible due to poor image acquisition quality. Exclusion of these patients resulted in a sample size of 118 patients who had undergone elective resection for CRC. Distribution of CCR7+ cells in CRC Staining was achieved in all 118 specimens with the majority showing homogeneous staining but, as expected, different intensities were frequently observed. Staining expression of CCR7 was observed mainly at the tumour margin, and stroma but also in the primary tumour. Image software analysis from all the specimens revealed a median tumor infiltrating CCR7+ cell density of 15.85 % (Inter Quartile Range (IQR) 10.02-21.83 %) in the tumor stroma, and 7.17 % (IQR 3.90-12.37 %) at the tumor margin. CCR7+ cell density of the two areas correlated positively (Spearman r = 0.77; p<0.001). The median CCR7+ cell density for the tumour cells was 16.78 % (IQR 7.28-22.76). We divided the cases into high and low CCR7+ groups according to the median value of CCR7 + cell density. Figure 1 demonstrates the distribution of CCR7+ cells in CRC. CCR7+ cells and clinical and pathological parameters High CCR7+ cell density at both the tumor center and the margin was significantly associated with older age, higher tumor stage, lymph node metastasis and the presence of myosteatosis. High CCR7+ cell density at the tumor margin was also significantly associated with female sex and the presence of lymphovascular invasion. There was no significant association between CCR7+ cell density either at the margin or within an intra-tumoral location with BMI, site of tumor, grade of differentiation, myopenia or visceral adiposity. A high KM grade was identified in 38 % of the cases studies and this was significantly associated with the CCR7+ cell density at the tumour margin but not in the stroma. High density of CCR7+ tumour cells was significantly associated with higher tumor stage, lymph node metastasis and the presence of lymphovascular invasion. Table 1 demonstrates the correlation between tumorinfiltrating CCR7+ cell density and clinicopathological factors in patients with CRC who had been treated surgically. CCR7+ cells and Clinical Outcome of Colorectal Cancer Among the 118 patients, there were 13 recurrences and 18 deaths during a median 40-month follow-up (IQR 15-50 months). Kaplan–Meier analysis demonstrated that high CCR7+ cell density at the tumor margin was significantly associated with shorter disease-free and overall survival (log-rank test, p=0.031 and p=0.022; respectively). Figure 2 demonstrates the Kaplan-Meier graphs of CRC overall survival (OS) and disease free survival (DFS) after resection for CRC according to CCR7+ cell density at the tumor margin and the stroma. To determine the independent prognostic significance of CCR7+ cell density on DFS and OS, multivariate analysis using a Cox proportional hazards model was performed. High CCR7+ cell density at the tumor margin was significantly associated with shorter DFS and OS in multivariate regression analysis (HR=8.87; 95%CI (2.51-31.3); p<0.01 for OS and HR=4.72; 95%CI (1.24-12.9) p=0.02 for DFS) as outlined in Table 2. However a high CCR7+ cell density in the tumor margin or in the tumour cells was not an independent prognostic factor for DFS or OS in this study. Lymph node metastasis and grade of differentiation were identified as being independently prognostic factors for OS and grade of differentiation was also an independent prognostic factor for DFS. Discussion We found that a high density of tumor-infiltrating CCR7+ cells was significantly associated with age, histological invasion, higher tumor stage, lymph node metastasis, high grade of inflammatory response (KM score), and myosteatosis that are adverse prognostic factors in CRC. Moreover, high CCR7+ cell density in the tumor margin was significantly associated with shorter DFS and OS. Our findings suggest that tumor-infiltrating CCR7+ cells are associated with a more aggressive cancer. The mechanisms by which LIR affects prognosis in patients with CRC are not clear. We found an association between infiltration of CCR7+ cells, at the tumor margin and within the tumor stroma, with some of the clinicopathological variables examined. In particular, high CCR7 density in the tumor margin and stroma were directly correlated with adverse prognostic factors such as increased age, advanced T and N stage and the presence of myosteatosis. These findings may therefore suggest a model whereby the stimulus for the local immune cell response is not only induced by the tumor but also influenced by host-related factors. Recent work from our group has demonstrated an association between myosteatosis and the presence of an altered systemic inflammatory response in patients treated for CRC. [6] We have now identified that myosteatosis is also related to an adverse local inflammatory response as measured by a high CCR7 density. To our knowledge these findings are novel and may support the hypothesis that host LIR may influence the development and persistence of myosteatosis. Retrospective studies on various cancers have shown that tumor cells express CCR7, including breast, [19] melanoma, [20] oesophageal, [21] lung, [22] head and neck [23] and CRC.[24] Ongoing oncogenic mutagenesis within the tumor can lead to increased expression of chemokine receptors including CCR7, but also tumor-derived factors such as VEGF and PGE2 may contribute to this overexpression.[25-27] Therefore, increased expression of CCR7 on immune cells infiltrating the tumor mass can be attributed to this tumor behavior. Increased on-going chemokine production by the tumor will attract immune cells and upregulate the expression of CCR7. [28] In our study, we have specifically focused on the critical interface between tumor and the stroma and the margin excluding tumor tissue itself. Therefore, CCR7+ cells from our study will mainly consist of immune cells known to express CCR7, such as T cells, antigen presenting cells and stroma cells. This is further supported by the observation that high expression of CCR7 at the tumour margin was strongly associated with high grade of inflammatory response measured with the KM score. The impact of CCR7+ non-tumor cells on CRC outcomes has been recorded previously, but the results were controversial: Gunther et al. studied the expression of CCR7 on paraffin-embedded tumor specimens of 99 all stages CRC patients and concluded that increased CCR7 expression at the invasion margin was associated with worse OS. [24] Similarly, Schimanski et al. studied the expression of CCR7 and another chemokine receptor, CXCR4, on tumor specimens of 96 CRC patients of all stages. [29] However, only increased CXCR4 expression was associated with poorer outcome, not CCR7 expression. Correale et al. studied the expression of CCR7 on tumor-infiltrating T cells in 76 patients with metastatic CRC. The results demonstrated that high expression of CCR7 positive tumor infiltrating lymphocyte, specifically CD8+ CCR7+ cells, was predictive of good outcome in patients with advanced CRC. [30] Previous studies have shown a beneficial role of infiltrating CD8+ cells in outcome in CRC. [31],[32],[33] Therefore, expression of CCR7 on CD8+ cells in CRC could correlate with improved outcome, especially in advanced CRC. In the present study, on a population of 118 patients with non-metastatic CRC, multivariate analyses demonstrated that high CCR7+ cell density at the tumor margin is significantly associated with shorter DFS and OS. Our results suggest that CCR7+ cell density at the tumor margin may be a novel prognostic biomarker to predict outcomes in patients with early CRC. Our analyses showed that in the tumor periphery, high CCR7+ cell density was associated with high KM score. A recent study reported that high KM score correlated with markers of infiltrated peritumoural inflammatory cells (CD3, CD8, CD68 and FoxP3 cells), but no association was identified with dendritic cell density determined using CD1a+ cells. [34] Therefore, it is possible to infer that CCR7 positivity in our study was mainly due to expression on the inflammatory cells described above. Our results also suggest that despite increased LIR in the tumor peripheries (demonstrated by high KM score), high expression of CCR7 in these immune cells may have an impact and key role for the development of an efficient immune response. This highlights the importance of determining the characteristics of tumor infiltrating inflammatory cells, rather than only the density or count of inflammatory cells determined by KM score. This study has a number of limitations. The identification and classification of specific cell types expressing CCR7 was not performed. However, the main aim of this work was to investigate the overall stromal expression of CCR7 in the tumor margin and the stroma of the colorectal tissues and whether this expression is an indicator of undesirable prognosis in patients with CRC. Results were encouraging and pave the way to assess the prognostic value of the expression of CCR7 on particular cell types, which will be the subject of future work. Although CCR7 expression was observed on the tumour cells we focused only on the tumor margin and stroma. The primary reason for this approach is that the tumor stroma and margin represent a vital compartment of the tumor microenvironment that reflects LIR, affects tumor progression and metastasis [35] and also because the expression of CCR7 on tumor cells has been previously reported. In summary, our data give additional support to the prognostic significance of the LIR in CRC. Moreover, our results suggest that CCR7 positive cell density at the tumor margin may be a novel prognostic biomarker to predict outcomes in patients with CRC. Acknowledgements The authors thank Matt Ellis for recommendations and assistance and R. Baldwin for retrieving and preparing for analysis the CT images. HOA was supported by a grant from the Association of International Cancer Research (AICR) Scotland, Grant number 120234. References 1. Brenner H, Kloor M, Pox CP: Colorectal cancer. Lancet 2014;383:14901502. 2. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008;454:436-444. 3. Jass JR: Lymphocytic infiltration and survival in rectal cancer. Journal of clinical pathology 1986;39:585-589. 4. Richards CH, Roxburgh CS, MacMillan MT, et al.: The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PloS one 2012;7:e41883. 5. Roxburgh CS, McMillan DC: Cancer and systemic inflammation: treat the tumour and treat the host. British journal of cancer 2014;110:1409-1412. 6. Malietzis G, Johns N, Al-Hassi HO, et al.: Low Muscularity and Myosteatosis Is Related to the Host Systemic Inflammatory Response in Patients Undergoing Surgery for Colorectal Cancer. Ann Surg 2015. 7. Wang ZM, Pierson RN, Jr., Heymsfield SB: The five-level model: a new approach to organizing body-composition research. The American journal of clinical nutrition 1992;56:19-28. 8. Miljkovic I, Zmuda JM: Epidemiology of myosteatosis. Current opinion in clinical nutrition and metabolic care 2010;13:260-264. 9. Doyle SL, Bennett AM, Donohoe CL, et al.: Establishing computed tomography-defined visceral fat area thresholds for use in obesityrelated cancer research. Nutrition research 2013;33:171-179. 10. Baracos V, Kazemi-Bajestani SM: Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses. The international journal of biochemistry & cell biology 2013;45:2302-2308. 11. Zlotnik A, Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-127. 12. Forster R, Davalos-Misslitz AC, Rot A: CCR7 and its ligands: balancing immunity and tolerance. Nature reviews Immunology 2008;8:362-371. 13. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010;140:883-899. 14. Mei Z, Liu Y, Liu C, et al.: Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. British journal of cancer 2014;110:1595-1605. 15. Malietzis G, Aziz O, Bagnall NM, et al.: The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: A systematic review. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2014. 16. Klintrup K, Makinen JM, Kauppila S, et al.: Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005;41:2645-2654. 17. Mourtzakis M, Prado CM, Lieffers JR, et al.: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme 2008;33:997-1006. 18. Martin L, Birdsell L, Macdonald N, et al.: Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31:1539-1547. 19. Muller A, Homey B, Soto H, et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56. 20. Takeuchi H, Fujimoto A, Tanaka M, et al.: CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10:2351-2358. 21. Ding Y, Shimada Y, Maeda M, et al.: Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9:3406-3412. 22. Takanami I: Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. International journal of cancer Journal international du cancer 2003;105:186-189. 23. Mburu YK, Egloff AM, Walker WH, et al.: Chemokine receptor 7 (CCR7) gene expression is regulated by NF-kappaB and activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN). The Journal of biological chemistry 2012;287:3581-3590. 24. Gunther K, Leier J, Henning G, et al.: Prediction of lymph node metastasis in colorectal carcinoma by expressionof chemokine receptor CCR7. International journal of cancer Journal international du cancer 2005;116:726-733. 25. Chuang CW, Pan MR, Hou MF, Hung WC: Cyclooxygenase-2 upregulates CCR7 expression via AKT-mediated phosphorylation and activation of Sp1 in breast cancer cells. Journal of cellular physiology 2013;228:341-348. 26. Wang D, DuBois RN: An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer journal 2013;19:502-510. 27. Issa A, Le TX, Shoushtari AN, et al.: Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer research 2009;69:349-357. 28. Balkwill FR: The chemokine system and cancer. The Journal of pathology 2012;226:148-157. 29. Schimanski CC, Schwald S, Simiantonaki N, et al.: Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11:1743-1750. 30. Correale P, Rotundo MS, Botta C, et al.: Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18:850-857. 31. Naito Y, Saito K, Shiiba K, et al.: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer research 1998;58:3491-3494. 32. Pages F, Kirilovsky A, Mlecnik B, et al.: In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27:5944-5951. 33. Ling A, Edin S, Wikberg ML, et al.: The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. British journal of cancer 2014;110:2551-2559. 34. Vayrynen JP, Tuomisto A, Klintrup K, et al.: Detailed analysis of inflammatory cell infiltration in colorectal cancer. British journal of cancer 2013;109:1839-1847. 35. Quail DF, Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nature medicine 2013;19:1423-1437. Figure Legends Figure 1 CCR 7 cell immunohistochemistry shows high (A,C) and low (B,D) infiltration of CCR7+ cells in the stroma (A,B) and the tumour periphery (C,D). Figure 2 Kaplan-Meier graphs of colorectal cancer overall survival (OS) (a,b) and disease free survival (DFS)(c, d) after resection for CRC according to CCR7+ cell density at the tumour periphery (a,c) and stroma (b,d).